`
`http://www.bausch.com/our-company/investor-relations#.VkphGivz5Kj
`
`M B 5 United States
`B A U S C II If
`See better. Live better.
`
`Newsroom Careers
`Contact Us
`
`Investor Relations
`
`Ezfgggtiaarl:
`
`Text size A- A+
`
`0urProducts
`
`Wsionaidltge
`
`YourEyeconcerns
`
`Oilcompany
`
`Search.“
`
`Home > Our Company > Investor Relations
`
`Investor Relations
`
`Llre
`
`5
`
`Tweet
`
`0
`
`Vdeant Phamiaceuticals International, Inc., (NYSE: VRX) (TSX: VRX) completed its acqlisition of Bausch + Lomb on August
`5, 2013. Bausch + Lomb will retfli its name and become a division of Valeant. Valeant's existing ophthalmology businesses
`wiIIbeiitegratedintolheBausch+Lorribdivision, creatilgaglobdeyeheallhplatformwithestimatedproformazotanet
`revenue of more than $3.5 billion. For Investor Relations iifomiation on VaIeant_ click here.
`
`V» ........... lll n n - - » A u n x.
`v ru
`V A L E A N T
`
`Vision and Eye Health
`Vision and Age
`Eye Infections & Irritations
`Diseases and Disorders
`Find a Doctor
`Eiizye Exam Check l_ist
`
`Products
`Contact Lenses
`Contact Lens Care
`Dry Eye Products
`AlergyIRedne$ Relief
`Rx Pharmaceutical
`Eye Wtamins
`Sugical Products
`wsion Accessories
`
`customer support
`Contact Us
`Customer policies and forms
`Rebate Center
`Worldwide Locations
`
`Legal
`Legal Notice
`Privacy Policy
`Safety Data Sheets (SDS)
`
`News
`ca|'ee[5
`Imesgor Regafions
`Gmms 3 cmmbufions
`
`0 2015 Bausch 8. Lomb Incorporated.
`
`All ilformation and materials on this site pertain to the U.S. only, unless otherwise iiricated.
`
`PAGE 1 OF 1
`
`lofl
`
`LUPIN v SENJU
`IPR2015—01l05
`11/16/2015 6:05 PM